iMetabolic Biopharma Corporation
iMetabolic Biopharma Corporation (iMBP) is a biopharmaceutical company focused on tackling the global obesity epidemic and its related comorbidities. They are pioneering the future of healthcare with their groundbreaking TechBio AI technology and proprietary iPlatform. This platform utilizes in-silico therapeutic discovery and molecular design to accelerate and improve the efficiency of drug development, offering significant economic and time-saving advantages. iMBP's mission is to create safer, more effective, and affordable therapeutics. They have established key strategic partnerships and are developing a pipeline of drug candidates targeting cardiovascular diseases, metabolic diseases, and neurodegenerative diseases, including Alzheimer's.
iMetabolic Biopharma Corporation
iMetabolic Biopharma Corporation (iMBP) is a biopharmaceutical company focused on tackling the global obesity epidemic and its related comorbidities. They are pioneering the future of healthcare with their groundbreaking TechBio AI technology and proprietary iPlatform. This platform utilizes in-silico therapeutic discovery and molecular design to accelerate and improve the efficiency of drug development, offering significant economic and time-saving advantages. iMBP's mission is to create safer, more effective, and affordable therapeutics. They have established key strategic partnerships and are developing a pipeline of drug candidates targeting cardiovascular diseases, metabolic diseases, and neurodegenerative diseases, including Alzheimer's.